Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050240081> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2050240081 endingPage "963" @default.
- W2050240081 startingPage "961" @default.
- W2050240081 abstract "ObjectivesBosentan, a dual endothelin receptor antagonist (ERA), was the first oral drug approved for the treatment of pulmonary arterial hypertension (PAH), a rare disease with poor prognosis. In 2004 the Australian Department of Health agreed to fund bosentan on the pharmaceutical benefits scheme (PBS) on the condition that a registry was established to monitor mortality: if the observed mortality rate was higher than that claimed in the original funding submission then the price of bosentan would be reduced to maintain the original incremental cost-effectiveness ratio (ICER). This article presents the economic implications of the bosentan patient registry (BPR).MethodsAn existing economic model was updated using the results of the BPR.ResultsParticipation rates were high and the BPR collected 821 patient years of follow-up on 528 patients. Based on the observed raw mortality a 23.7% price reduction would have been needed to maintain the original ICER in idiopathic PAH patients. After allowing for the higher risk patients actually treated in Australia, a 13.5% reduction in bosentan price would have been required. In 2008, however, sitaxentan, a new oral ERA PAH treatment was listed on the PBS at a 15% discount to bosentan. On the basis of cost-minimization, bosentan was forced to reduce its price to that of sitaxentan. After this price reduction the ICER for bosentan was similar to that originally proposed and hence, no additional price reduction was sought by the Pharmaceutical Benefits Advisory Committee (PBAC).ConclusionsThe bosentan PAH registry provided a useful mechanism for monitoring the cost-effectiveness of bosentan after funding approval." @default.
- W2050240081 created "2016-06-24" @default.
- W2050240081 creator A5018526269 @default.
- W2050240081 creator A5041942546 @default.
- W2050240081 creator A5048306200 @default.
- W2050240081 date "2011-09-01" @default.
- W2050240081 modified "2023-09-30" @default.
- W2050240081 title "Funding Linked to Ongoing Research: Impact of the Bosentan Patient Registry on Pricing in Australia" @default.
- W2050240081 cites W1483490421 @default.
- W2050240081 cites W1793838897 @default.
- W2050240081 cites W1974227996 @default.
- W2050240081 cites W1985704557 @default.
- W2050240081 cites W1985832932 @default.
- W2050240081 cites W2013010309 @default.
- W2050240081 cites W2022866202 @default.
- W2050240081 cites W2048443661 @default.
- W2050240081 cites W2059037762 @default.
- W2050240081 cites W2066154306 @default.
- W2050240081 cites W2097973238 @default.
- W2050240081 cites W2101469388 @default.
- W2050240081 cites W2160425825 @default.
- W2050240081 cites W2182875431 @default.
- W2050240081 doi "https://doi.org/10.1016/j.jval.2011.02.1177" @default.
- W2050240081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21914519" @default.
- W2050240081 hasPublicationYear "2011" @default.
- W2050240081 type Work @default.
- W2050240081 sameAs 2050240081 @default.
- W2050240081 citedByCount "11" @default.
- W2050240081 countsByYear W20502400812012 @default.
- W2050240081 countsByYear W20502400812013 @default.
- W2050240081 countsByYear W20502400812014 @default.
- W2050240081 countsByYear W20502400812015 @default.
- W2050240081 countsByYear W20502400812018 @default.
- W2050240081 countsByYear W20502400812019 @default.
- W2050240081 countsByYear W20502400812022 @default.
- W2050240081 crossrefType "journal-article" @default.
- W2050240081 hasAuthorship W2050240081A5018526269 @default.
- W2050240081 hasAuthorship W2050240081A5041942546 @default.
- W2050240081 hasAuthorship W2050240081A5048306200 @default.
- W2050240081 hasBestOaLocation W20502400811 @default.
- W2050240081 hasConcept C126322002 @default.
- W2050240081 hasConcept C144980905 @default.
- W2050240081 hasConcept C170493617 @default.
- W2050240081 hasConcept C177713679 @default.
- W2050240081 hasConcept C2781109936 @default.
- W2050240081 hasConcept C71924100 @default.
- W2050240081 hasConceptScore W2050240081C126322002 @default.
- W2050240081 hasConceptScore W2050240081C144980905 @default.
- W2050240081 hasConceptScore W2050240081C170493617 @default.
- W2050240081 hasConceptScore W2050240081C177713679 @default.
- W2050240081 hasConceptScore W2050240081C2781109936 @default.
- W2050240081 hasConceptScore W2050240081C71924100 @default.
- W2050240081 hasIssue "6" @default.
- W2050240081 hasLocation W20502400811 @default.
- W2050240081 hasLocation W20502400812 @default.
- W2050240081 hasOpenAccess W2050240081 @default.
- W2050240081 hasPrimaryLocation W20502400811 @default.
- W2050240081 hasRelatedWork W1995515455 @default.
- W2050240081 hasRelatedWork W2040429290 @default.
- W2050240081 hasRelatedWork W2102344094 @default.
- W2050240081 hasRelatedWork W2185480050 @default.
- W2050240081 hasRelatedWork W2401235024 @default.
- W2050240081 hasRelatedWork W2748952813 @default.
- W2050240081 hasRelatedWork W2899084033 @default.
- W2050240081 hasRelatedWork W2981515574 @default.
- W2050240081 hasRelatedWork W3031052312 @default.
- W2050240081 hasRelatedWork W3032375762 @default.
- W2050240081 hasVolume "14" @default.
- W2050240081 isParatext "false" @default.
- W2050240081 isRetracted "false" @default.
- W2050240081 magId "2050240081" @default.
- W2050240081 workType "article" @default.